Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study

Objectives: The impact of non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and tumor necrosis factor inhibitors (TNFi) on the outcomes of mild-moderate COVID-19 in patients with ankylosing spondylitis (AS) remains unclear. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Hu, Zhengyuan, Guo, Yufei, Zhao, Zheng, Li, Kunpeng, Wang, Xiuru, Zhang, Jie, Liang, Dongfeng, Zhang, Jianglin, Hu, Xiaoyue, Zhu, Jian, Huang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642246/
https://www.ncbi.nlm.nih.gov/pubmed/37964869
http://dx.doi.org/10.3389/fphar.2023.1266915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642246/
https://www.ncbi.nlm.nih.gov/pubmed/37964869
http://dx.doi.org/10.3389/fphar.2023.1266915

Ejemplares similares